Today's Peptide Chemists Face A Dizzying Array Of Synthesizer Choices

Times have certainly changed since the first automated peptide synthesizer hit the market in the mid-1980s. Early machines were capable of processing one peptide at a time, a major improvement over manually adding reagents, washing between reactions, and moving on to the next step. You just set up the synthesizer, and in the morning there was your peptide. Nowadays, the choices are growing, as more manufacturers offer instruments for large-scale preparation or for multiple, simultaneous prepara

Written byScott Veggeberg
| 9 min read

Register for free to listen to this article
Listen with Speechify
0:00
9:00
Share

Moreover, there is now one instrument on the market, with the possibility of others to come, that allows control of reaction temperature and atmosphere. Such instruments are intended as general-purpose organic synthesizers capable of stringing together a variety of reactants, not only for peptide synthesis but also for oligonucleotide synthesis or for use in combinatorial chemistry, in which complex multifunctional molecules are built up from a pantheon of monomers.

The array of choices in peptide synthesizers is almost dizzying, especially when one considers that only about 1,000 automated synthesizers are currently installed and about 200 to 300 are sold each year, according to industry sources. Industry insiders report that today there are five major manufacturers of peptide synthesizers in terms of sales, with an aggregate of 10 individual units on the market and two more soon to be released. Each product is intended for a different type of user. They ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies